For the current fiscal year, the ADMA Biologics, Inc. (NASDAQ:ADMA) may present ($0.21) earnings per share, expects Wall Street brokerages as reported by Zacks Investment Research. The earnings of ADMA Biologics have been estimated by four analysts. The highest EPS estimate is ($0.19) and the lowest is ($0.21). In the previous year for the same quarter, the company recorded the same EPS. This indicates a 10.5% negative year-over-year growth rate.
NASDAQ:ADMA Analysts’ Report
On Wednesday, 4th November, the company will declare its earnings for next quarter. According to analysts, ADMA Biologics (NASDAQ:ADMA) should record ($0.89) per share in its full-year earnings for the current fiscal year. The EPS should range between ($0.90) and ($0.86). Few research firms that follow ADMA Biologics have reported the EPS calculations to Zacks Investment Research.
On Wednesday, 5th August, ADMA Biologics announced its earnings results. The company, opposing the ($0.16) by ($0.07) estimated consensus recorded an EPS of ($0.23) for the quarter. The analysts estimated the quarterly revenue of ADMA Biologics (NASDAQ:ADMA) to be $10.29 million.
But the biotechnology company reported $7.79 million in revenue. ADMA Biologics reported a negative return on equity and a negative net margin of 104.32% and 164.90%, respectively. The ADMA shares have been reported by various equities analysts. On Thursday, 6th August, in a research result, Oppenheimer assumed coverage of ADMA Biologic (NASDAQ:ADMA)’ shares. A price target of $6.00 and a ‘buy’ rating was issued to the company by them.
On Thursday, 6th August, HC Wainwright set a target price of $12.00 on the company’s shares and reissued the ‘buy’ rating. On Thursday, 1st October, the price target on ADMA Biologics (NASDAQ:ADMA)’s shares was increased from $7.00 to $9.00 by Raymond James. It also issued an ‘outperform’ rating.
On Friday, 14th August, BidaskClub shifted NASDAQ:ADMA’s rating from ‘sell’ to ‘strong sell.’ On Tuesday, 18th August, ADMA Biologics’ shares were downgraded from a ‘hold’ rating to a ‘sell’ rating by Zacks Investment Research.
The stocks have fetched a ‘sell’ rating by four analysts and a ‘buy’ rating by five analysts. ‘Hold’ is the average rating of the company’s shares and $8.25 is the consensus target price.
ADMA Biologics (NASDAQ:ADMA): Other News
On Wednesday, 12th August, Director Jerrold B. Grossman acquired 10,200 shares of the company’s stock. The total value of the stock was $29,478.00 and the average price per share was $2.89.
45,5000 shares worth $121,386 were bought by insiders in the past three months. Insiders own 11.70 % of ADMA Biologics (NASDAQ:ADMA)’s stock.
The company shares were recently bought and sold by a few institutional investors and hedge funds. During the 1st quarter, the holdings in the company were raised by 5.3%.
